These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 16913202)

  • 21. Clinical problem-solving. Simple and complex.
    Leng S; Nallamothu BK; Saint S; Appleman LJ; Bump GM
    N Engl J Med; 2013 Jan; 368(1):65-71. PubMed ID: 23281978
    [No Abstract]   [Full Text] [Related]  

  • 22. [The O'Brien filter test in the differential diagnosis of disorders with high-grade thrombocytosis].
    Rejtö L; Schlammadinger A; László P; Kiss A; Telek B; Boda Z
    Orv Hetil; 1998 Aug; 139(33):1961-4. PubMed ID: 9734213
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Portal or hepatic vein thrombosis as the first presentation of a myeloproliferative disorder in patients with normal peripheral blood counts.
    McNamara C; Juneja S; Wolf M; Grigg A
    Clin Lab Haematol; 2002 Aug; 24(4):239-42. PubMed ID: 12181028
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Long-term interferon therapy for thrombocytosis in myeloproliferative diseases.
    Gisslinger H; Ludwig H; Linkesch W; Chott A; Fritz E; Radaszkiewicz T
    Lancet; 1989 Mar; 1(8639):634-7. PubMed ID: 2564458
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Which tests are most useful in distinguishing between reactive thrombocytosis and the thrombocytosis of myeloproliferative disease?
    Randi ML; Fabris F; Rossi C; Girolami A
    Clin Lab Haematol; 1992; 14(3):267-8. PubMed ID: 1451409
    [No Abstract]   [Full Text] [Related]  

  • 26. The diagnostic value of the serum lactic dehydrogenase determination in the evaluation of unexplained thrombocytosis.
    Budman DR; Lackner H; Berczeller P; Silber R
    Am J Clin Pathol; 1981 Jun; 75(6):840-3. PubMed ID: 6942650
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Analysis of risk factors: the rationale of the guidelines of the Czech Hematological Society for diagnosis and treatment of chronic myeloproliferative disorders with thrombocythemia.
    Schwarz J; Pytlík R; Doubek M; Brychtová Y; Dulícek P; Campr V; Kren L; Penka M
    Semin Thromb Hemost; 2006 Apr; 32(3):231-45. PubMed ID: 16673277
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Therapy of thrombocytosis in myeloproliferative syndromes using recombinant interferon-alpha-2a].
    Tichelli A; Gratwohl A; Delacrétaz F; Dazzi H; Stebler C; Wernli M; Holdener EE; Nissen C; Speck B
    Schweiz Med Wochenschr; 1989 Sep; 119(39):1347-52. PubMed ID: 2799342
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The role of platelets in the pathogenesis of thrombosis and hemorrhage in patients with thrombocytosis.
    Walsh PN; Murphy S; Barry WE
    Thromb Haemost; 1977 Dec; 38(4):1085-96. PubMed ID: 579686
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Extreme thrombocytosis: what are the etiologies?
    Wiwanitkit V
    Clin Appl Thromb Hemost; 2006 Jan; 12(1):85-7. PubMed ID: 16444439
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Combined plateletpheresis and cytotoxic chemotherapy for symptomatic thrombocytosis in myeloproliferative disorders.
    Baron BW; Mick R; Baron JM
    Cancer; 1993 Aug; 72(4):1209-18. PubMed ID: 8339212
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Splenomegaly and the JAK2 V617F mutation.
    Langabeer SE
    Eur J Intern Med; 2017 Jan; 37():e45-e46. PubMed ID: 27727073
    [No Abstract]   [Full Text] [Related]  

  • 33. Anagrelide for thrombocytosis in myeloproliferative disorders: a prospective study to assess efficacy and adverse event profile.
    Steurer M; Gastl G; Jedrzejczak WW; Pytlik R; Lin W; Schlögl E; Gisslinger H
    Cancer; 2004 Nov; 101(10):2239-46. PubMed ID: 15476273
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Treatment of thrombocytosis in myeloproliferative disorders with interferon alpha-2a.
    Tichelli A; Gratwohl A; Berger C; Lori A; Würsch A; Dieterle A; Thomssen C; Nissen C; Holdener E; Speck B
    Blut; 1989 Jan; 58(1):15-9. PubMed ID: 2644994
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Thrombocytosis. Diagnostic orientation].
    Guilhot F
    Rev Prat; 1992 Feb; 42(3):357-8. PubMed ID: 1579830
    [No Abstract]   [Full Text] [Related]  

  • 36. Extreme thrombocytosis and cardiovascular surgery: risks and management.
    Natelson EA
    Tex Heart Inst J; 2012; 39(6):792-8. PubMed ID: 23304015
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The role of thrombocytapheresis in the contemporary management of hyperthrombocytosis in myeloproliferative neoplasms: A case-based review.
    Boddu P; Falchi L; Hosing C; Newberry K; Bose P; Verstovsek S
    Leuk Res; 2017 Jul; 58():14-22. PubMed ID: 28380402
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Platelet function in patients with high platelet counts.
    Ginsburg AD
    Ann Intern Med; 1975 Apr; 82(4):506-11. PubMed ID: 1054537
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Myeloproliferative disorders--neurological complications.
    Tarach JS; Nowicka-Tarach BM
    Med Sci Monit; 2000; 6(2):421-5. PubMed ID: 11208349
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Medical Grand Rounds--chronic granulocytic leukemia with thrombocytosis; the hypercoagulability states.
    Kossmann CE; Hubbard WS; Chesney CM
    J Tenn Med Assoc; 1981 Oct; 74(10):742-3, 745. PubMed ID: 6947124
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.